Neuroscience
Congress Materials – World Congress of Neuropsychopharmacology (CINP 2026)
2026 World Congress of Neuropsychopharmacology | Jun 26-29 | Glasgow, UK
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Efficacy and Safety of Adjunctive Lumateperone 42 mg in Major Depressive Disorder: A Pooled Analysis of Demographic and Clinical Subgroups From Two Phase 3 Randomized Placebo-Controlled Trials
Willie R. Earley; Suresh Durgam; Changzheng Chen; Raffaele Migliore; Susan G. Kornstein; Roger S. McIntyre; Maurizio Fava
Efficacy of Adjunctive Lumateperone 42 mg Treatment Across Patient-Reported Depression Symptoms in Major Depressive Disorder
Willie R. Earley; Suresh Durgam; Raffaele Migliore; YifanMo; Hassan Lakkis; Susan G. Kornstein; Maurizio Fava
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.